Coherent Market Insights published a business research report on Novel Drugs and Devices to Lower Intraocular Pressure Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2022–2028. Novel Drugs and Devices to Lower Intraocular Pressure Market with 150+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items.
The global Novel Drugs and Devices to Lower Intraocular Pressure Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Novel Drugs and Devices to Lower Intraocular Pressure Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/2670
Intraocular pressure (IOP) is the fluid pressure inside the eye. IOP is an important aspect in the evaluation of patients at risk of glaucoma. The aqueous humor of the ciliary body in the eye is responsible for IOP. The production and expulsion rate of aqueous humor by the ciliary body determines the pressure in the eye. The presence of excess fluid creates pressure in the eye which may lead to glaucoma. Glaucoma are of two types, such as closed–angle and open–angle glaucoma. Tonometry is the method eye care professionals use to determine this.
Drivers:
Increasing prevalence of glaucoma and frequent approvals and launches of novel products are expected to augment growth of the global novel drugs and devices to lower intraocular pressure market. For instance, in August 2018, the United States Food and Drug Administration (FDA) approved Ivantis Inc.’s Hydrus Microstent, a device used for microinvasive glaucoma surgery (MIGS) in patients with mild to moderate primary open-angle glaucoma.
Moreover, in September 2018, FDA approved latanoprost ophthalmic emulsion (Xelpros, Sun Pharmaceuticals) to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, the company has announced.
Furthermore, players in the market are focusing on launching new and approved products (drugs and devices) to treat glaucoma (Intraocular pressure), which in turn is also expected to augment the growth of the market. For instance, in December 2017, Aerie Pharmaceuticals received FDA approval for Rhopressa to treat glaucoma. Now, Aerie is studying the Rhopressa for its long-term effects on patients with ocular hypertension and open angle glaucoma.
Restraints:
The risk of side effects associated with glaucoma medications is expected to hamper the growth of the global novel drugs and devices to lower intraocular pressure market. Side effects may include stinging corneal deposits, and internal bleeding.
Moreover, high cost of glaucoma medications is expected to hinder growth of the market. For instance, 2.5 milliliter’s of Rhopressa (Netarsudil ophthalmic solution) costs around US$ 269.
Market Taxonomy:
By Treatment Type:
- Drug (Rhopressa, Roclatan, Xelpros, Vyzulta, and Others)
- Device (Implant, Therapeutic Ultrasound, and Others)
By Distribution Channel:
- Hospitals & Clinics
- Retail Channel
- Online Channels
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Regional Analysis:
Among regions, North America is expected to witness robust growth in the global novel drugs and devices to lower intraocular pressure market due to the high prevalence of glaucoma and favorable government initiatives in the region. For instance, in May 2019, Glaucoma Research Foundation (US) launched the third phase of its collaborative research program, the Catalyst for a Cure Vision Restoration Initiative to find a cure for glaucoma.
Competitive Landscape:
Key players active in the global novel drugs and devices to lower intraocular pressure market are Pfizer Inc., Glaukos Corporation, Alcon Inc., Allergan, Bausch & Lomb Inc., Eye Sonix, IOPtima Ltd., BioLight Lifesciences Ltd., Mati Therapeutics Inc, and Sun Pharmaceutical Industries Ltd., among others.
Buy This Report With USD 2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/2670
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Novel Drugs and Devices to Lower Intraocular Pressure Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Novel Drugs and Devices to Lower Intraocular Pressure Industry Impact
Chapter 2 Global Novel Drugs and Devices to Lower Intraocular Pressure Competition by Types, Applications, and Top Regions and Countries
2.1 Global Novel Drugs and Devices to Lower Intraocular Pressure (Volume and Value) by Type
2.3 Global Novel Drugs and Devices to Lower Intraocular Pressure (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Novel Drugs and Devices to Lower Intraocular Pressure Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Novel Drugs and Devices to Lower Intraocular Pressure Market Analysis
Chapter 6 East Asia Novel Drugs and Devices to Lower Intraocular Pressure Market Analysis
Chapter 7 Europe Novel Drugs and Devices to Lower Intraocular Pressure Market Analysis
Chapter 8 South Asia Novel Drugs and Devices to Lower Intraocular Pressure Market Analysis
Chapter 9 Southeast Asia Novel Drugs and Devices to Lower Intraocular Pressure Market Analysis
Chapter 10 Middle East Novel Drugs and Devices to Lower Intraocular Pressure Market Analysis
Chapter 11 Africa Novel Drugs and Devices to Lower Intraocular Pressure Market Analysis
Chapter 12 Oceania Novel Drugs and Devices to Lower Intraocular Pressure Market Analysis
Chapter 13 South America Novel Drugs and Devices to Lower Intraocular Pressure Market Analysis
Chapter 14 Company Profiles and Key Figures in Novel Drugs and Devices to Lower Intraocular Pressure Business
Chapter 15 Global Novel Drugs and Devices to Lower Intraocular Pressure Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
Continued….
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/2670
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837